Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aclarion, Inc. (ACON)
USD2.64
-0.03 (-1.12%)
US NASDAQ Healthcare Medical - Healthcare Information Services
Address
951 Mariners Island Boulevard 94404
Broomfield, CA, US
Broomfield, CA, US
CEO
Brent Ness
Website
aclarion.com
IPO
2022-04-22
CIK 1635077 ISIN US6551874091
Also trades on
NASDAQ Capital Market · ACON (USD)
NASDAQ Capital Market · ACONW (USD)
Description
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.64
-0.03 (-1.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
106.2K
Beta
1.22
Float Shares
533.3K
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.86% | -1.56% | -6.78% | +22.01% | -47.51% | -31.30% | -55.93% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
2.64
DCF (Unlevered)
22,584,539.19
+855,474,869.3%
DCF (Levered)
22,584,536.50
+855,474,767.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-3.37
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%+65.6% ★ Q1'26: +11.3% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+99.8% ★ Q1'26: +85.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-9,513.3% Q1'26: -12,496.9% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-9,312.6% Q1'26: -14,129.3% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+0.0% Q1'26: -1,839.5% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+56,329.2% Q1'26: +870.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
75.4K
est: 53.9K (+39.8%)
|
45.7K
est: 55.0K (-16.9%)
|
75.7K
est: 77.0K (-1.6%)
|
139.0K
139.0K – 139.0K
+80.5% YoY
|
| EBITDA |
-4.14M
est: -53.9K (-7,575.0%)
|
-6.26M
est: -55.0K (-11,289.7%)
|
-6.82M
est: -77.0K (-8,763.6%)
|
-139.0K
-139.0K – -139.0K
-80.5% YoY
|
| EBIT |
-4.30M
est: -53.9K (-7,876.5%)
|
-6.46M
est: -55.0K (-11,640.8%)
|
-7.05M
est: -77.0K (-9,058.9%)
|
-139.0K
-139.0K – -139.0K
-80.5% YoY
|
| Net Income |
-4.91M
est: -844.4K (-481.7%)
|
-6.99M
est: -3.92B (+99.8%)
|
-7.23M
est: -8.05M (+10.1%)
|
-2.33M
-2.33M – -2.33M
+71.1% YoY
|
| SGA |
4.00M
est: 858.46B (-100.0%)
|
4.59M
est: 875.21B (-100.0%)
|
6.03T
est: 1.23T (+391.8%)
|
2.21T
2.21T – 2.21T
+80.5% YoY
|
| EPS |
-79,782.00
est: -1.59 (-5,027,026.1%)
|
-7,480.22
est: -7,371.68 (-1.5%)
|
-13.61
est: -15.13 (+10.0%)
|
-4.37
-4.37 – -4.37
+71.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.42B
OE per share TTM
2,365.34
Owner's Yield
21,154.33%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6,147,661.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
4
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NuVasive, Inc. | 1.13M | 14.40% | 1.13M | — | 1.13M | — | CO | Delaware | 2023-02-03 | ↗ |
| 2 | Joseph Reda | 1.00M | 9.90% | 500.0K | 500.0K | 500.0K | 1.00M | IN | United States | 2024-09-05 | ↗ |
| 3 | SEG Opportunity Fund, LLC | 500.0K | 4.90% | — | 500.0K | — | 500.0K | OO | New York | 2024-09-05 | ↗ |
| 4 | Daniel B. Asher | 375.6K | 4.99% | — | 375.6K | — | 375.6K | HC, IN | United States of America | 2024-03-06 | ↗ |
| 5 | Intracoastal Capital LLC | 375.6K | 4.99% | — | 375.6K | — | 375.6K | OO | United States of America | 2024-03-06 | ↗ |
| 6 | Mitchell P. Kopin | 375.6K | 4.99% | — | 375.6K | — | 375.6K | HC, IN | United States of America | 2024-03-06 | ↗ |
| 7 | White Lion Capital, LLC | 80.0K | 9.52% | 80.0K | 80.0K | 80.0K | 80.0K | OO | Nevada | 2024-01-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 21.7K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
16.0K
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+16,015
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Breidbart Scott | Director | P-Purchase | A | Common Stock | 5,664 | 3.18 | 18.0K | 5,664 | D | ↗ |
| 2026-05-11 | Ness Brent | Director / Officer | P-Purchase | A | Common Stock | 6,289 | 3.18 | 20.0K | 6,300 | D | ↗ |
| 2026-05-11 | Neal David K | Director | P-Purchase | A | Common Stock | 2,500 | 3.10 | 7.8K | 2,502 | D | ↗ |
| 2026-05-06 | Wesemann William | Director | P-Purchase | A | Common Stock | 1,562 | 3.30 | 5.2K | 1,563 | D | ↗ |
| 2025-11-26 | Ness Brent | Director / Officer | P-Purchase | A | Common Stock | 10 | 6.20 | 62.00 | 11 | D | ↗ |
| 2025-09-02 | Gould Gregory A | Officer | A-Award | A | Stock Option (right to buy) | 17,000 | 7.15 | 121.6K | 17,000 | D | ↗ |
| 2023-03-28 | Thramann Jeffrey John | Officer | J-Other | D | Series A Preferred Stock | 1 | 1,000.00 | 1.0K | 0 | — | ↗ |
| 2023-02-16 | Thramann Jeffrey John | Director / Officer | P-Purchase | A | Series A Preferred Stock | 1 | 1,000.00 | 1.0K | 1 | — | ↗ |
| 2022-12-29 | Wesemann William | Director | A-Award | A | Stock option (right to buy) | 63,000 | 0.00 | — | 63,000 | — | ↗ |
| 2022-12-29 | Ness Brent | Officer | P-Purchase | A | Common Stock | 7,711 | 0.58 | 4.5K | 19,500 | — | ↗ |
| 2022-12-29 | Lorbiecki John Paul | Officer | P-Purchase | A | Common Stock | 4,100 | 0.43 | 1.8K | 4,100 | — | ↗ |
| 2022-12-28 | Ness Brent | Officer | P-Purchase | A | Common Stock | 2,289 | 0.42 | 961.38 | 3,289 | — | ↗ |
| 2022-12-02 | SC Capital 1 LLC | Director | J-Other | D | Common Stock | 1,091,894 | 0.00 | — | 0 | — | ↗ |
| 2022-12-02 | Neal David K | Director | J-Other | D | Common Stock | 152,128 | 0.00 | — | 186,528 | — | ↗ |
| 2022-04-22 | Sequira Amanda Mae | Director | A-Award | A | Stock option (right to buy) | 63,000 | 0.00 | — | 63,000 | — | ↗ |
| 2022-04-22 | Deitsch Stephen | Director | A-Award | A | Stock option (right to buy) | 63,000 | 2.72 | 171.4K | 63,000 | — | ↗ |
| 2022-04-22 | Breidbart Scott | Director | A-Award | A | Stock option (right to buy) | 63,000 | 0.00 | — | 63,000 | — | ↗ |
| 2022-04-22 | Bond Ryan | Officer | P-Purchase | A | Warrants for Common Stock (right to buy) | 21,000 | 0.73 | 15.3K | 48,527 | — | ↗ |
| 2022-04-21 | Wesemann William | Director | — | D | Employee Stock Option (right to buy) | 10,040 | 1.94 | 19.5K | 0 | — | ↗ |
| 2022-04-21 | Thramann Jeffrey John | Director / Officer | — | D | Employee Stock Option (right to buy) | 1,204,819 | 1.94 | 2.34M | 0 | — | ↗ |
| 2022-04-21 | Sequira Amanda Mae | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-21 | SC Capital 1 LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,091,894 | — | ↗ |
| 2022-04-21 | Ness Brent | Director / Officer | — | D | Employee Stock Option (right to buy) | 341,365 | 1.94 | 662.2K | 0 | — | ↗ |
| 2022-04-21 | Neal David K | Director | — | D | Employee Stock Option (right to buy) | 66,934 | 1.94 | 129.9K | 0 | — | ↗ |
| 2022-04-21 | NUVASIVE INC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,126,495 | — | ↗ |
| 2022-04-21 | Lorbiecki John Paul | Officer | — | D | Employee Stock Option (right to buy) | 66,934 | 1.94 | 129.9K | 0 | — | ↗ |
| 2022-04-21 | Deitsch Stephen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-21 | Breidbart Scott | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-21 | Bond Ryan | Officer | — | D | Employee Stock Option (right to buy) | 6,108 | 1.94 | 11.8K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-14.1K
Shares Outstanding
533.3K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brent Ness | Chief Executive Officer, President & Director | 462.5K | male |
| Jeffrey John Thramann | Executive Chairman | 462.5K | — |
| Gregory A. Gould | Chief Financial Officer | 297.6K | male |
| Ryan Bond | Chief Strategy Officer | 254.2K | male |
ESG Rating
ESG Score History MEDICAL - HEALTHCARE INFORMATION SERVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACON
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
